REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIEWBIX INC. (Exact name of registrant as specified in its charter) As filed with the Securities and Exchange Commission on May 14, 2025 Registration No. 333-281143 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 3 Hanehoshet St, Building B, 7th floor Tel Aviv, Israel 6971068 +972-9774-1505 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code ...

Core Viewpoint - West Red Lake Gold Mines Ltd. has drawn the final tranche of US$12.5 million from a US$35 million credit facility with Nebari Natural Resources Credit Fund II LP to support the restart of the Madsen Mine and other corporate expenses [1][3]. Credit Facility Details - The credit facility was established on December 31, 2024, with the first drawdown of US$15 million and a second tranche of US$7.5 million [2]. - The repayment structure includes 50% of the principal being repaid via fixed straight-line amortization starting 15 months after the first tranche drawdown, with the remaining 50% due at maturity on June 30, 2028 [4][6]. - Interest on the loan will be based on a floating rate, which includes the three-month term SOFR plus 8.0% per annum, with a minimum interest rate of 4.0% [5]. Use of Proceeds - The proceeds from the final tranche will be allocated to complete capital costs for restarting the Madsen Mine and cover other corporate, exploration, and working capital expenses [3]. Warrants Issued - In connection with the final tranche, the company issued 4,158,875 non-transferable common share purchase warrants at an exercise price of CAD$0.85, expiring on June 30, 2028 [7]. - The warrants represent 20% of the loan amount drawn in the final tranche, subject to a statutory hold period of four months and one day [8]. Company Overview - West Red Lake Gold Mines Ltd. is focused on advancing its flagship Madsen Gold Mine and holds a significant land package in the Red Lake district of Ontario, known for its high-grade gold deposits [10].

Core Viewpoint - Altimmune, Inc. has secured a credit facility of up to $100 million from Hercules Capital to support the development of its novel peptide-based therapeutic, pemvidutide, aimed at treating liver and cardiometabolic diseases [1][2]. Financial Strength and Flexibility - The credit facility enhances Altimmune's balance sheet, which had $150 million in cash and cash equivalents as of March 31, 2025 [2]. - The initial tranche of $15 million will be drawn at closing, with additional funds available upon meeting specific clinical and financial milestones [3]. Development Plans for Pemvidutide - Pemvidutide is currently in a Phase 2b trial for metabolic dysfunction-associated steatohepatitis (MASH), with top-line data expected in Q2 2025 [2]. - Phase 2 trials for pemvidutide in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) are anticipated to start in the second and third quarters of 2025, respectively [2]. Partnership and Future Outlook - The partnership with Hercules Capital is expected to extend Altimmune's cash runway under flexible terms, allowing for continued development of pemvidutide [3]. - Hercules Capital expresses enthusiasm in supporting Altimmune through its clinical development journey, particularly with the upcoming data release from the IMPACT trial [3]. Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases, with pemvidutide as its lead program [4].